计算溶液所需的质量、体积或浓度。
| 活性类型 | Relation | Activity value | Units | Action Type | 期刊 | PubMed Id | doi | Assay Aladdin ID |
|---|
提供 ≥98% 纯度,适用于对基线干扰要求严格的色谱和分析工作流程。
2-8°C储存,干燥。低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
PF-543 Citrate (Sphingosine Kinase 1 Inhibitor II Citrate) is a potent, selective, reversible and sphingosine-competitive SPHK1 inhibitor with an IC 50 of 2 nM and a K i of 3.6 nM. PF-543 Citrate is >100-fold selectivity for SPHK1 over SPHK2 . PF-543 Citrate is an effective potent inhibitor of sphingosine 1-phosphate (S1P) formation in whole blood with an IC 50 of 26.7 nM. PF-543 Citrate induces apoptosis , necrosis, and autophagy
In Vitro
PF-543 (10-1000 nM; 24?hours; PASM cells) treatment abolishes SK1 expression at nM concentrations. ?\nPF-543 (0.1-10 μM; 24 hours; PASM cells) treatment induces caspase-3/7 activity. ?\nPF-543 inhibits C 17 -S1P formation in 1483 cells with an IC 50 of 1.0 nM. ?\nSphK1 inhibition by PF-543 causes a dose-dependent depletion of the intracellular level of S1P with EC 50 concentration of 8.4 nM and a concomitant elevation of the intracellular level of sphingosine in 1483 cells. The level of endogenous S1P in 1483 cells after a 1 h treatment with 200 nM PF-543 is decreased 10-fold, producing a proportional increase in the level of sphingosine. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot AnalysisCell Line: Human pulmonary arterial smooth muscle (PASM) cells Concentration: 10 nM, 100 nM, 1000 nM Incubation Time: 24 hours Result: Abolished SK1 expression at nM concentrations. Apoptosis AnalysisCell Line: Human pulmonary arterial smooth muscle (PASM) cells Concentration: 0.1 μM, 1 μM, 10 μM Incubation Time: 24 hours Result: Induced caspase-3/7 activity in cultured human pulmonary smooth muscle cells.
In Vivo
PF-543 (1 mg/kg; intraperitoneal injection; every second day; for 21 days; female C57BL/6 J mice) treatment has no effect on vascular remodelling but reduces right ventricular hypertrophy. The protection involves a reduction in the expression of p53 and an increase in the expression of anti-oxidant nuclear factor Nrf-2. ?\nMice are initially dosed (ip) with 10 mg/kg or 30 mg/kg of PF-543 for 24 h and the T 1/2 is 1.2 h in blood samples. Administration of 10 mg/kg PF-543 for 24 h to mice induces a decrease in SK1 expression in pulmonary vessels. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Female C57BL/6 J mice (7-12 week-old) with hypoxic-induced pulmonary arterial hypertensionDosage: 1 mg/kg Administration: Intraperitoneal injection; every second day; for 21 days Result: Reduced right ventricular hypertrophy. The protection involves a reduction in the expression of p53 (that promotes cardiomyocyte death) and an increase in the expression of anti-oxidant nuclear factor Nrf-2.
Form:Solid
IC50& Target:SphK1
分类树(Taxonomy Tree)
| 界(kingdom) | 有机化合物 |
|---|---|
| 超类(Superclass) | 有机酸及其衍生物 |
| 类(Class) | 羧酸及其衍生物 |
| 亚类(Subclass) | 三羧酸及其衍生物 |
| 中间层级节点(Intermediate Tree Nodes) | 暂无 |
| 直接上位类(Direct Parent) | 三羧酸及其衍生物 |
| 其他上位类(Alternative Parents) | 苯磺酰基化合物 苄胺 苯甲胺 苯氧基化合物 酚醚 烷基芳基醚 甲苯 芳烷基胺 α-羟基酸及其衍生物 N-烷基吡咯烷 砜类 叔醇 1,2-氨基醇 三烷基胺 羧酸 氮杂环化合物 碳氢化合物衍生物 羰基化合物 伯醇 有机氧化物 |
| 分子骨架(Molecular Framework) | 暂无 |
| 取代基(Substituents) | 1,2-氨基醇 - 羟基苯甲酸酯 - 芳基醚 - α-羟基酸 - 氨基酸 - 芳烷基胺 - 芳香族杂单环化合物 - 氮杂环 - 苯磺酰基 - 苯基化合物 - 苄胺 - 羰基 - 羧酰胺基 - 乙醚 - 烃衍生物 - 羟基酸 - 单环苯基基团 - N-烷基吡咯烷 - 有机硝基化合物 - 有机氧化物 - 有机氧化合物 - 有机杂环化合物 - 有机氮化合物 - 有机氧化合物 - 有机硫化合物 - 苯酚醚 - 苯氧基化合物 - 苯甲胺 - 初级醇 - 吡咯烷 - 磺酰基 - 磺酰基 - 三烷基醇 - 三元脂肪胺 - 三芳基胺 - 甲苯 - 三羧酸或其衍生物 |
| 描述(Description) | 该化合物属于三羧酸及其衍生物类有机化合物。此类化合物为含三个羧基的羧酸。 |
| 外部描述符(External Descriptors) | 暂无 |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|